Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA NEW YORK and LONDON

Akari Therapeutics Granted FDA Rare Pediatric

Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

NEW YORK and LONDON, November 10, 2022 (GLOBE

NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and

inflammatory diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the Rare Pediatric Disease Designation

to nomacopan for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Rare

Pediatric Disease Designation is an important addition to the Orphan Drug and Fast Track designations previously granted by the FDA for

nomacopan in pediatric HSCT-TMA.

"Families with children who have a hematopoietic

stem cell transplant-related TMA face grim prospects with high mortality rates and no approved treatment options," said Rachelle

Jacques, President and CEO of Akari. "The Rare Pediatric Disease Designation was created by the FDA because families need so much

more than hope for their children, they need meaningful treatment options. We are pleased the FDA has recognized the significant needs

that exist for children with HSCT-TMA, and we will continue to urgently pursue our mission to advance nomacopan to approval on their behalf."

The FDA Rare Pediatric Disease Designation and

Voucher Program is a recognition of the significant need that exists for approved treatments in rare pediatric diseases and is intended

to encourage development of these treatments. Under this program, a sponsor who receives an approval of a new drug application (NDA) or

biologics license application (BLA) for a rare pediatric disease may be eligible for a Priority Review Voucher (PRV). A PRV is valuable

because it can be redeemed to obtain priority review for a subsequent marketing application for a different product or may be sold to

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology

company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific

recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial

program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA),

as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute

"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking

statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information

currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and

prospects as reflected in or suggested by those forward- looking statements are reasonable, we can give no assurance that the plans, intentions,

expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the

forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties

for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going

concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory

approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan

drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical

results for nomacopan and any other product candidates and unexpected costs that may result there; difficulties enrolling patients in

our clinical trials; failure to realize any value of nomacopan and any other product candidates developed and being developed in light

of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates

and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other

competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may

not be as large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents

and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and

maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities;

the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company

depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S.

Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise

noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise

any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable

reliance on the forward-looking statements contained in this press release.

For more information

Schleifstein PR (917) 763-8106